Chemical compound
Pharmaceutical compound
Tasosartan is an angiotensin II receptor antagonist.
It was withdrawn from FDA review by the manufacturer after phase III clinical trials showed elevated transaminases (a sign of possible liver toxicity) in a significant number of participants given the drug.[1][2]
References
|
|---|
ACE inhibitors
("-pril") |
- Sulfhydryl-containing: Captopril
- Rentiapril
- Zofenopril (+nebivolol)
- Dicarboxylate-containing: Enalapril# (+lercanidipine, +nitrendipine)
- Benazepril (+amlodipine, +pimobendan)
- Cilazapril
- Delapril (+manidipine)
- Imidapril
- Lisinopril (+amlodipine, +HCT)
- Moexipril
- Perindopril (+amlodipine, +bisoprolol, +indapamide, +amlodipine and indapamide, +bisoprolol and amlodipine, +bisoprolol, amlodipine, and indapamide)
- Quinapril (+HCT)
- Ramipril (+amlodipine, +amlodipine and HCT, +bisoprolol, +felodipine)
- Spirapril
- Temocapril
- Trandolapril (+verapamil)
- Phosphonate-containing: Ceronapril
- Fosinopril (+HCT)
- Other/ungrouped: Alacepril
|
|---|
AIIRAs
("-sartan") |
- Azilsartan
- Candesartan (+amlodipine, +amlodipine and HCT)
- Eprosartan
- Fimasartan
- Irbesartan (+amlodipine, +amlodipine and HCT, +HCT)
- Losartan (+amlodipine, +HCT)
- Olmesartan (+amlodipine, +amlodipine and HCT, +HCT)
- Tasosartan§
- Telmisartan (+amlodipine, +amlodipine and HCT, +HCT)
- Valsartan (+aliskiren, +amlodipine, +amlodipine and HCT, +HCT, +lercanidipine, +nebivolol, +sacubitril)
|
|---|
Renin inhibitors
("-kiren") | |
|---|
| Dual ACE/NEP inhibitors | |
|---|
| Neprilysin inhibitors | |
|---|
| Other | |
|---|
|
|
|---|
| ATRTooltip Angiotensin receptor | |
|---|
| Combinations: | |
|---|
